Tecan Group (TECN.SW) Stock Price

Tecan Group Price

SIX·CLOSED
195.10CHF+3.30 (+1.71 %)
Market closed

Revenue has compounded at 4.2% per year over the past 19 years to 882.48 M CHF. Earnings per share have grown at 2.3% per year over the last 18 years. Tecan Group's net margin stands at -12.5%, down from 12.9% several years earlier. Tecan Group currently offers a dividend yield of about 0.77%. The dividend has grown at 6.5% per year over the past 19 years. Analysts set a median price target of 168.30 CHF, implying 13.7% below the current price. Of 13 analysts, 8 rate the stock a buy — an overall Buy consensus. The stock trades about 72% above its 52-week low.

Tecan Group stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Tecan Group over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Tecan Group stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Tecan Group's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Tecan Group Stock Price History
DateTecan Group Price
8/7/2026195.10 CHF
8/6/2026191.80 CHF
8/5/2026193.80 CHF
8/4/2026196.20 CHF
8/3/2026192.90 CHF
7/31/2026186.10 CHF
7/30/2026186.60 CHF
7/29/2026185.50 CHF
7/28/2026179.40 CHF
7/27/2026179.20 CHF
7/24/2026182.20 CHF
7/23/2026176.30 CHF
7/22/2026178.90 CHF
7/21/2026181.40 CHF
7/20/2026178.70 CHF
7/17/2026181.00 CHF
7/16/2026182.40 CHF
7/15/2026183.60 CHF
7/14/2026185.00 CHF
7/13/2026182.40 CHF
7/10/2026182.90 CHF
7/9/2026175.00 CHF
7/8/2026168.50 CHF
7/7/2026172.30 CHF
7/6/2026175.90 CHF
7/3/2026176.80 CHF
7/2/2026180.30 CHF
7/1/2026175.60 CHF
6/30/2026161.80 CHF
6/29/2026163.00 CHF
6/26/2026162.60 CHF
6/25/2026165.90 CHF
6/24/2026155.70 CHF
6/23/2026150.00 CHF
6/22/2026150.40 CHF
6/19/2026149.80 CHF
6/18/2026146.80 CHF
6/17/2026148.60 CHF
6/16/2026147.70 CHF
6/15/2026149.90 CHF
6/12/2026150.60 CHF
6/11/2026153.40 CHF
6/10/2026154.00 CHF
6/9/2026154.00 CHF
6/8/2026152.60 CHF
6/5/2026164.00 CHF
6/4/2026160.50 CHF
6/3/2026155.90 CHF
6/2/2026159.80 CHF
6/1/2026154.60 CHF
5/29/2026155.20 CHF
5/28/2026151.20 CHF
5/27/2026152.50 CHF
5/26/2026148.90 CHF
5/22/2026150.00 CHF
5/21/2026147.50 CHF
5/20/2026143.20 CHF
5/19/2026142.70 CHF
5/18/2026136.60 CHF
5/15/2026134.70 CHF
5/13/2026133.20 CHF
5/12/2026135.20 CHF
5/11/2026131.50 CHF
5/8/2026131.80 CHF
5/7/2026131.60 CHF
5/6/2026132.90 CHF
5/5/2026125.00 CHF
5/4/2026123.40 CHF
4/30/2026117.70 CHF
4/29/2026115.40 CHF
4/28/2026117.70 CHF
4/27/2026119.10 CHF
4/24/2026124.20 CHF
4/23/2026127.80 CHF
4/22/2026134.80 CHF
4/21/2026137.30 CHF
4/20/2026135.50 CHF
4/17/2026138.00 CHF
4/16/2026139.80 CHF
4/15/2026141.40 CHF
4/14/2026140.90 CHF
4/13/2026134.50 CHF
4/10/2026134.90 CHF
4/9/2026131.60 CHF
4/8/2026135.50 CHF
4/7/2026135.70 CHF
4/2/2026136.00 CHF
3/27/2026129.00 CHF
3/26/2026127.43 CHF
3/25/2026126.70 CHF
3/24/2026124.00 CHF
3/23/2026113.13 CHF
3/21/2026116.10 CHF
3/19/2026118.10 CHF
3/17/2026121.50 CHF
3/16/2026116.97 CHF
3/13/2026120.55 CHF
3/12/2026124.86 CHF
3/11/2026125.75 CHF
3/10/2026126.00 CHF
3/9/2026125.99 CHF
3/6/2026129.93 CHF
3/5/2026130.60 CHF
2/27/2026136.30 CHF
2/26/2026134.91 CHF
2/25/2026133.64 CHF
2/23/2026134.50 CHF
2/20/2026134.10 CHF
2/19/2026135.00 CHF
2/18/2026135.39 CHF
2/17/2026129.90 CHF
2/16/2026129.85 CHF
2/13/2026131.46 CHF
2/12/2026129.35 CHF
2/11/2026134.80 CHF
2/10/2026134.80 CHF
2/9/2026132.80 CHF
2/6/2026135.12 CHF
2/5/2026135.90 CHF
2/4/2026136.00 CHF
2/3/2026132.89 CHF
2/2/2026133.80 CHF
1/30/2026136.00 CHF
1/29/2026136.00 CHF
1/28/2026137.56 CHF
1/27/2026139.63 CHF
1/26/2026139.00 CHF
1/23/2026142.90 CHF
1/22/2026143.60 CHF
1/21/2026142.87 CHF
1/20/2026140.16 CHF
1/19/2026143.96 CHF
1/16/2026148.40 CHF
1/15/2026148.36 CHF
1/14/2026159.03 CHF
1/13/2026158.85 CHF
1/9/2026151.25 CHF
1/8/2026139.63 CHF
1/6/2026136.88 CHF
1/5/2026130.52 CHF
12/30/2025128.32 CHF
12/29/2025129.10 CHF
12/24/2025128.20 CHF
12/23/2025129.70 CHF
12/22/2025127.77 CHF
12/19/2025127.20 CHF
12/18/2025125.05 CHF
12/17/2025123.70 CHF
12/16/2025125.38 CHF
12/15/2025124.60 CHF
12/12/2025127.10 CHF
12/11/2025128.70 CHF
12/10/2025130.48 CHF
12/9/2025131.30 CHF
12/8/2025131.47 CHF
12/5/2025133.70 CHF
12/4/2025133.70 CHF
12/3/2025135.82 CHF
12/2/2025135.70 CHF
12/1/2025138.40 CHF
11/28/2025138.05 CHF
11/27/2025139.05 CHF
11/26/2025139.47 CHF
11/25/2025139.70 CHF
11/24/2025137.00 CHF
11/21/2025134.75 CHF
11/20/2025133.45 CHF
11/19/2025134.40 CHF
11/18/2025134.95 CHF
11/17/2025138.91 CHF
11/15/2025139.70 CHF
11/13/2025141.01 CHF
11/12/2025138.58 CHF
11/11/2025137.08 CHF
11/10/2025136.00 CHF
11/7/2025134.97 CHF
11/6/2025138.40 CHF
11/5/2025138.04 CHF
11/4/2025139.86 CHF
10/31/2025145.62 CHF
10/30/2025148.89 CHF
10/29/2025148.59 CHF
10/28/2025150.07 CHF
10/27/2025150.83 CHF
10/25/2025153.19 CHF
10/23/2025153.77 CHF
10/22/2025150.19 CHF
10/21/2025149.64 CHF
10/20/2025145.16 CHF
10/17/2025145.29 CHF
10/16/2025143.02 CHF
10/15/2025140.60 CHF
10/14/2025140.10 CHF
10/13/2025141.20 CHF
10/10/2025148.71 CHF
10/9/2025150.81 CHF
10/8/2025152.37 CHF
10/7/2025157.06 CHF
10/6/2025156.63 CHF
10/3/2025154.19 CHF
10/2/2025152.51 CHF
10/1/2025147.08 CHF
9/29/2025145.50 CHF
9/26/2025145.60 CHF
9/25/2025149.40 CHF
9/24/2025155.70 CHF
9/23/2025156.98 CHF
9/22/2025159.26 CHF
9/19/2025156.57 CHF
9/18/2025158.89 CHF
9/17/2025157.19 CHF
9/16/2025156.37 CHF
9/15/2025157.20 CHF
9/12/2025157.64 CHF
9/11/2025154.66 CHF
9/10/2025153.25 CHF
9/9/2025152.21 CHF
9/8/2025155.04 CHF
9/5/2025156.64 CHF
9/4/2025154.36 CHF
9/3/2025158.36 CHF
9/2/2025159.11 CHF
9/1/2025164.80 CHF
8/29/2025163.50 CHF
8/28/2025167.86 CHF
8/27/2025168.93 CHF
8/26/2025172.00 CHF
8/25/2025174.55 CHF
8/22/2025174.25 CHF
8/21/2025172.38 CHF
8/20/2025171.05 CHF
8/19/2025170.80 CHF
8/18/2025169.28 CHF
8/15/2025170.10 CHF
8/14/2025167.28 CHF
8/13/2025169.00 CHF
8/12/2025171.28 CHF
8/11/2025154.70 CHF
Access this data via the Eulerpool API
Get Free API Key

Tecan Group Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
1.07 B CHF
135.97 M CHF
132.08 M CHF
Jan 1, 2024
934.28 M CHF
75.57 M CHF
67.66 M CHF
Jan 1, 2025
882.48 M CHF
25.24 M CHF
-110.65 M CHF
Jan 1, 2026 (e)
883.64 M CHF
91.28 M CHF
79.52 M CHF
Jan 1, 2027 (e)
929.52 M CHF
95.91 M CHF
96.23 M CHF
Jan 1, 2028 (e)
982.83 M CHF
101.55 M CHF
113.66 M CHF
Jan 1, 2029 (e)
1.05 B CHF
108.34 M CHF
136.36 M CHF
Jan 1, 2030 (e)
1.10 B CHF
114.16 M CHF
145.64 M CHF

Tecan Group Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 11, 2026, 7:06 AM
 
REVENUEB CHF
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM CHF
EBITM CHF
EBIT MARGIN%
NET INCOMEM CHF
NET INCOME GROWTH%
DIV.CHF
DIV. GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
0.440.510.550.590.640.730.951.141.070.930.880.880.930.981.051.10
10.2815.008.308.217.2514.7829.5920.93-6.12-13.04-5.570.115.215.716.725.34
48.8647.2348.1846.8844.3446.4441.0135.4036.3134.2631.7531.7531.7531.7531.7531.75
215.00239.00264.00278.00282.00339.00388.00405.00390.00320.00280.00280.32294.92311.75332.70350.48
66.0068.0081.0087.0088.00122.00141.00145.00135.0075.0025.0091.0095.00101.00108.00114.00
15.0013.4414.7814.6713.8416.7114.9012.6712.578.032.8310.3110.2310.2910.3110.33
57.0054.0066.0070.0073.00103.00121.00121.00132.0067.00-110.0079.0096.00113.00136.00145.00
42.50-5.2622.226.064.2941.1017.48–9.09-49.24-264.18-171.8221.5217.7120.356.62
1.501.751.752.002.101.101.151.401.451.501.501.601.701.81––
–16.67–14.295.00-47.624.5521.743.573.45–6.676.256.47––
11.4211.6811.8811.8811.9611.9612.9212.8412.8412.7612.6712.6712.6712.6712.6712.67
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Tecan Group generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Tecan Group retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Tecan Group's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Tecan Group has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Tecan Group's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Tecan Group stock margins

The Tecan Group margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Tecan Group. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Tecan Group.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
40.99 %
14.91 %
12.85 %
Jan 1, 2022
35.42 %
12.76 %
10.59 %
Jan 1, 2023
36.34 %
12.66 %
12.29 %
Jan 1, 2024
34.32 %
8.09 %
7.24 %
Jan 1, 2025
31.75 %
2.86 %
-12.54 %
Jan 1, 2026 (e)
31.75 %
10.33 %
9.00 %
Jan 1, 2027 (e)
31.75 %
10.32 %
10.35 %
Jan 1, 2028 (e)
31.75 %
10.33 %
11.56 %

Tecan Group Stock Revenue, EBIT, Earnings per Share

The Tecan Group earnings per share therefore indicates how much revenue Tecan Group has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
73.26 CHF
10.92 CHF
9.42 CHF
Jan 1, 2022
89.15 CHF
11.37 CHF
9.44 CHF
Jan 1, 2023
83.66 CHF
10.59 CHF
10.28 CHF
Jan 1, 2024
73.24 CHF
5.92 CHF
5.30 CHF
Jan 1, 2025
69.66 CHF
1.99 CHF
-8.73 CHF
Jan 1, 2026 (e)
69.79 CHF
7.21 CHF
6.28 CHF
Jan 1, 2027 (e)
73.41 CHF
7.57 CHF
7.60 CHF
Jan 1, 2028 (e)
77.62 CHF
8.02 CHF
8.98 CHF

Tecan Group business model & stock analysis

Tecan Group AG is a Swiss company specializing in the development and manufacture of laboratory automation systems. It was founded in 1980 in Männedorf, a suburb of Zurich, by engineer Heinz Abplanalp and currently employs approximately 1,400 people worldwide. Tecan's business model focuses on supporting customers in the medical and pharmaceutical research and development fields with laboratory process automation. The goal is to save time and costs while improving the quality of results. Tecan offers a wide range of products and services for this purpose. One of Tecan's key areas is the production of robotic systems for sample processing in clinical diagnostics and drug research. These systems can automatically fill, mix, separate, and analyze samples in tubes or microplates. Automating these processes minimizes errors and achieves significant time savings. Another area is the manufacturing of laboratory equipment and instruments, such as pipettes, microplate readers, or washing stations. These products enable laboratories to process a variety of samples quickly and accurately capture data. The products are sold under various brand names, including Tecan, Cavro, and Debiotech. A significant milestone in Tecan's history was the introduction of the first microplate reader in 1988. Since then, the company has continuously improved the technology and now offers a wide range of microplate readers for various applications. Another important development was the introduction of the Freedom EVO® robotics system in 2000, which has become a key tool in clinical diagnostics and drug research. Tecan also provides a range of service offerings, including installation, training, and maintenance of automated laboratory equipment. Additionally, the company offers customized automation solutions tailored to its customers' specific requirements. In recent years, Tecan has expanded into the field of liquid handling robotics to offer customers new opportunities to automate their workflows. This includes automatic pipetting systems that offer high precision and reproducibility, increasing productivity in research and development. Despite its long history, Tecan has faced some challenges in recent years. In 2021, the company acquired IDS Imaging Development Systems to expand its robotics systems in laboratory diagnostics and life sciences. Tecan also sees itself increasingly as part of the industry's digital transformation, relying on artificial intelligence, machine learning, robotics, and automation to support its customers in addressing the changing laboratory requirements. Overall, Tecan is an important player in the laboratory technology industry, earning a reputation with its robotic systems and automation solutions. The company has continuously evolved over the past decades and now offers its customers a wide range of products and services to optimize and accelerate their research and development processes.

Tecan Group SWOT Analysis

Strengths

Tecan Group AG holds several key strengths that contribute to its success in the market.

  • Strong Brand Reputation: Tecan is recognized as a leading provider of automation and detection solutions.
  • Technological Expertise: The company invests heavily in research & development, allowing it to deliver innovative and high-quality products.
  • Diverse Product Portfolio: Tecan offers a broad range of laboratory instruments and consumables, catering to various customer needs.
  • Strong Global Presence: With a wide distribution network and subsidiaries worldwide, Tecan has established a strong international foothold.

Weaknesses

Despite its strengths, Tecan Group AG faces certain weaknesses that pose challenges to its growth.

  • Competitive Pressure: The market for laboratory solutions is highly competitive, making it challenging for Tecan to maintain market share.
  • Dependence on Third-Party Suppliers: Tecan relies on external suppliers for critical components, which may lead to supply chain disruptions.
  • High Research & Development Costs: Continuing innovation requires significant investments, which can impact profitability.

Opportunities

Tecan Group AG can leverage the following opportunities to drive future growth and expansion.

  • Rising Demand for Automated Solutions: The increasing adoption of automation in laboratories presents opportunities for Tecan to further penetrate the market.
  • Emerging Markets: Expanding into developing regions offers access to untapped customer segments and potential revenue growth.
  • Strategic Partnerships: Collaborating with key stakeholders, such as research institutions and pharmaceutical companies, can lead to joint product development and market expansion.

Threats

Tecan Group AG also faces certain threats that may hinder its growth and profitability prospects.

  • Intense Competition: Competitors with similar product offerings and established market presence pose a threat to Tecan's market share.
  • Economic Uncertainty: Fluctuating economic conditions, such as recessions or currency fluctuations, can impact customer spending on laboratory equipment and affect Tecan's revenue.
  • Regulatory Changes: Evolving regulatory standards and compliance requirements in the lab equipment industry may necessitate additional investments or hinder product development.

Tecan Group Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Tecan Group historical P/E ratio, EBIT multiple, and P/S ratio

Tecan Group annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Tecan Group shares outstanding

The number of shares of Tecan Group was 12.67 M in 2025. This indicates how many shares Tecan Group is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
12.92 M Stocks
Jan 1, 2022
12.84 M Stocks
Jan 1, 2023
12.84 M Stocks
Jan 1, 2024
12.76 M Stocks
Jan 1, 2025
12.67 M Stocks
Jan 1, 2026 (e)
12.67 M Stocks
Jan 1, 2027 (e)
12.67 M Stocks
Jan 1, 2028 (e)
12.67 M Stocks

Tecan Group stock splits

In Tecan Group's history, there have been no stock splits.

Tecan Group Dividend History

31 years of dividend payments

YearAnnual DividendYoY ChangePayments
20251.50CHF 0.0%1×
Apr 14, 20251.50CHF 0.0%1/1
20241.50CHF↑ 3.4%1×
20231.45CHF↑ 3.6%1×
20221.40CHF↑ 21.7%1×
20211.15CHF↑ 4.5%1×
20201.10CHF↓ 47.6%1×
20192.10CHF↑ 5.0%1×
20182.00CHF↑ 14.3%1×
20171.75CHF 0.0%1×
20161.75CHF↑ 16.7%1×

Tecan Group dividend history and estimates

In 2025, Tecan Group paid a dividend amounting to 1.50 CHF. Dividend means that Tecan Group distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Special dividend
Details
Date
Dividend
Dividend (Estimate)
Special dividend
Jan 1, 2021
1.15 CHF
0.00 CHF
0.00 CHF
Jan 1, 2022
1.40 CHF
0.00 CHF
0.00 CHF
Jan 1, 2023
1.45 CHF
0.00 CHF
0.00 CHF
Jan 1, 2024
1.50 CHF
0.00 CHF
0.00 CHF
Jan 1, 2025
1.50 CHF
0.00 CHF
0.00 CHF
Jan 1, 2026 (e)
0.00 CHF
1.60 CHF
0.00 CHF
Jan 1, 2027 (e)
0.00 CHF
1.70 CHF
0.00 CHF
Jan 1, 2028 (e)
0.00 CHF
1.81 CHF
0.00 CHF

Tecan Group dividend payout ratio

In 2025, Tecan Group had a payout ratio of -17.17%. The payout ratio indicates the percentage of the company's profits that Tecan Group distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
12.21 %
Jan 1, 2022
14.84 %
Jan 1, 2023
14.10 %
Jan 1, 2024
28.28 %
Jan 1, 2025
-17.17 %
Jan 1, 2026 (e)
25.41 %
Jan 1, 2027 (e)
22.34 %
Jan 1, 2028 (e)
20.13 %

Current Tecan Group forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
61.54 % (8)
Hold
30.77 % (4)
Sell
7.69 % (1)
12M Price Target
168.30
Last Price
202.00
Currency
CHF
12M Return Potential
-16.68 %
LTM Return
0 %

Tecan Group Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/16/20172.28CHF-255.37 MCHF-2017 Q2
8/16/20121.87CHF-193.13 MCHF-2012 Q2
8/18/20111.37CHF-167.92 MCHF-2011 Q2
3/10/20112.30CHF-191.48 MCHF-2010 Q4
8/12/20101.83CHF-184.15 MCHF-2010 Q2
8/13/20091.88CHF-189.55 MCHF-2009 Q2
3/4/20092.65CHF-217.16 MCHF-2008 Q4

EESG©

Eulerpool ESG Scorecard© for the Tecan Group stock

85/100
70
Environment
93
Social
91
Governance
E

Environment

20
Scope 1 - Direct Emissions2,010
Scope 2 - Indirect emissions from purchased energy7,908
Scope 3 - Indirect emissions within the value chain439,268
Total CO₂ emissions9,918
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees43.67
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Tecan Group shareholder structure

% Name
4.00282%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
3.42791%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
3.42448%
Norges Bank Investment Management (NBIM)
Norges Bank Investment Management (NBIM)
2.25261%
UBS Fund Management (Switzerland) AG
UBS Fund Management (Switzerland) AG
2.05013%
Invesco Advisers, Inc.
Invesco Advisers, Inc.
1.60548%
UBS Asset Management Switzerland AG
UBS Asset Management Switzerland AG
...

Tecan Group Beneficial Ownership Filings (SEC 13D/G)

Free Float
98.6%
Float Shares
-
Shares Outstanding
-

Tecan Group Executives and Management Board

16 members · avg. age 57 · 38 % women

AL

Dr. Achim Von Leoprechting (57)

Chief Executive Officer, Member of the Management Board

3.03 M CHF

Management

TM

Ms. Tania Micki (54)

Chief Financial Officer, Member of the Management Board

1.57 M CHF
MM

Ms. Monica Manotas (52)

Chief Executive Officer, Director · since 2024

66,000.00 CHF
IP

Ms. Ingrid Purgstaller (45)

Chief People Officer, Member of the Management Board

–
WY

Dr. Wael Yared (63)

Executive Vice President, Chief Technology Officer, Head Research and Development, Member of the Management Board

–
AW

Mr. Andreas Wilhelm (56)

Executive Vice President, General Counsel and Secretary of the Board of Directors, Member of the Management Board

–
MA

Ms. Mukta Acharya (41)

Executive Vice President, Head of the Life Sciences Business Division, Member of the Management Board

–

Board of Directors

LB

Dr. Lukas Braunschweiler (69)

Non-Executive Chairman of the Board

552,000.00 CHF
CK

Dr. Christa Kreuzburg (66)

Non-Executive Independent Director

280,000.00 CHF
MG

Mr. Matthias Gillner (58)

Non-Executive Director

272,000.00 CHF
ME

Ms. Myra Eskes (54)

Non-Executive Independent Director

262,000.00 CHF
OF

Dr. Oliver Fetzer (61)

Non-Executive Independent Director

254,000.00 CHF
DM

Dr. Daniel Marshak (68)

Non-Executive Director

251,000.00 CHF

Tecan Group Supply Chain

Tecan Group Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
20 companies
#Nameβ 1YTrend
1
Lonza Group
Customer·Life Sciences Tools & Services·CH
0.69
0.34
0.81
0.85
0.92
0.77
0.62
2
Sysmex
Customer·Health Care Equipment & Supplies·JP
-0.51
-0.12
0.53
0.90
0.86
0.76
0.98
3
QIAGEN
Supplier·Customer·Life Sciences Tools & Services·NL
0
-0.21
0.55
0.89
0.88
0.73
0.59
4
Agilent Technologies
Customer·Life Sciences Tools & Services·US
-0.52
0.06
0.82
0.93
0.93
0.69
0.71
5
JPMorgan Chase
Supplier·Customer·Banks·US
-0.29
-0.40
0.75
0.87
0.87
0.52
0.43
#Nameβ 1YTrend
1
Sansure Biotech A
Customer·Health Care Equipment & Supplies·CN
0.19
0.24
0.54
0.77
0.52
—
—
2
Codex DNA
Customer·Life Sciences Tools & Services·US
-0.61
0.06
0.60
0.43
—
—
—
3
Ortho Cli Dgnst Rg
Customer·Health Care Equipment & Supplies·US
-0.79
-0.03
0.42
0.53
0.56
—
—
4
DKSH Holding
Customer·Professional Services·CH
0.50
-0.07
-0.54
-0.83
-0.74
-0.02
-0.51
5
PeptiDream
Customer·Biotechnology·JP
0.39
-0.56
0.33
0.85
0.57
0.07
0.74

Frequently asked questions about Tecan Group

The business model of Tecan Group AG revolves around the development, manufacturing, and distribution of laboratory automation and detection solutions. Tecan offers a wide range of products and services that cater to various scientific research, diagnostics, and drug discovery applications. By providing innovative and reliable laboratory instruments, Tecan aims to enhance efficiency, accuracy, and productivity in the life science industry. With a focus on automation, Tecan's solutions enable scientists and researchers to streamline their workflows, improve data quality, and ultimately accelerate the pace of scientific discoveries. Tecan Group AG is committed to driving advancements in laboratory automation and empowering its customers in their quest for scientific breakthroughs.

Tecan Group AG is primarily active in the life sciences and clinical diagnostics industries.

The main competitors of Tecan Group AG in the market include companies such as PerkinElmer, Thermo Fisher Scientific, Danaher Corporation, and BioTek Instruments Inc. These companies operate in the life sciences and diagnostics sector, offering similar products and solutions. With its innovative technologies and extensive product portfolio, Tecan Group AG competes with these industry leaders to provide laboratories and research facilities with advanced laboratory automation systems, liquid handling solutions, and detection instruments.

Tecan Group AG, a leading Swiss biotechnology company, boasts a rich history and an impressive background. Founded in 1980, Tecan has been at the forefront of developing state-of-the-art laboratory instruments and solutions. With a global presence in over 52 countries, Tecan specializes in providing automated workflows for life science research, diagnostics, and clinical laboratories. This innovative company has consistently introduced groundbreaking technologies, such as robotics and liquid handling platforms, to enable faster and more efficient scientific discovery. With a relentless commitment to excellence, Tecan has earned a stellar reputation as a trusted partner in advancing scientific research and improving healthcare worldwide.

Tecan Group AG, a renowned biotechnology company, has achieved significant milestones over the years. One notable achievement is its establishment as a global leader in automated laboratory instruments and solutions. With its cutting-edge technology, Tecan has revolutionized the field of life sciences and diagnostics. The company's innovative products have enabled researchers and scientists worldwide to perform complex tasks efficiently and accurately. Moreover, Tecan has consistently expanded its product portfolio, introducing advanced platforms and solutions that cater to various scientific needs. This dedication to innovation and customer satisfaction has propelled Tecan Group AG to the forefront of the biotechnology industry, making it a trusted name among researchers and laboratories globally.

Tecan Group AG, a global leader in laboratory automation and detection solutions, has a strong presence in various countries and regions worldwide. The company operates in more than 50 countries, spanning North America, Europe, Asia-Pacific, and Latin America. With its headquarters in Switzerland, Tecan Group AG has established itself as a leading provider of innovative laboratory instruments and consumables across the globe.

Tecan Group AG represents a set of core values and a strong corporate philosophy. They prioritize innovation, quality, and customer focus in all their operations. With a commitment to excellence, Tecan strives to deliver cutting-edge solutions and services to their clients. Their corporate philosophy centers around fostering partnerships, integrity, and sustainability. Through continuous improvement and a dedication to their mission, Tecan aims to create long-term value for their shareholders and stakeholders. This Swiss-based company has a renowned reputation in the life sciences industry, constantly pushing boundaries and driving progress with their advanced laboratory automation and detection solutions.

Analysts currently set an average price target of 185.49 CHF for the Tecan Group stock (median: 168.30 CHF), implying -8.2 % versus the latest price. The consensus is based on 13 analyst ratings.

Tecan Group Analyst Price Targets 2026

13 analysts currently rate the Tecan Group stock: 8 recommend buying, 5 holding and 0 selling. For 2026, analysts expect Tecan Group to generate revenue of 883.64 M CHF and earnings per share of 6.28 CHF.

Tecan Group Analyst Price Targets 2026

Converted at the current exchange rate, the Tecan Group share trades at 208.69 EUR (195.10 CHF).

The Tecan Group share (TECN.SW) is listed on 6 stock exchanges, including: Frankfurt (TEN.F), München (TEN.MU), London (0QLN.L), London (0QLN.L), SIX (Zürich) (TECN.SW).

The Tecan Group AG is a globally leading company in the development, manufacturing, and marketing of laboratory automation solutions for the life science industry. The company's business model is based on the combination of high-quality instruments, software, and consumables to provide automation solutions for research institutions, diagnostic and pharmaceutical companies, as well as clinical and forensic analysis. Tecan consists of two business sectors: Life Sciences and Partnering Business. The Life Sciences sector includes the development and manufacturing of Tecan products for laboratory automation. This includes, for example, analysis and diagnostic devices, pipetting robots, extraction solutions, and software for laboratory automation. The Partnering Business involves the production of OEM instruments for partner companies, as well as collaboration with customers and partners in the development of custom solutions. Tecan's core product is the so-called Fluent Liquid Handling Workflow. This workflow accelerates the automation of laboratory tests in pharmaceutical companies, diagnostic and research institutions. The workflow consists of a combination of automated pipettes, sample handling, microplate management systems, and data management software. Tecan's focus is on automating workflows and improving efficiency in laboratory analysis. This is achieved by providing solutions for workflow and process automation, which in turn save time and resources and enhance accuracy in science. Another product portfolio of Tecan is its consumables. These are sold under the brand names Tecan, Cavro, TECAN PURE, and TECAN SELECT, and include tips, racks, plates, and seals that are tailored to the company's instruments. The consumables are offered in various sizes and formats and are suitable for a variety of applications in the life science industry. To provide the best possible service to its customers, Tecan maintains a large network of sales and service organizations in Europe, America, and Asia. These organizations offer comprehensive technical support and advice in solving problems that may occur during the operation of Tecan instruments. Overall, Tecan's business model is focused on providing effective and automated solutions for laboratory automation. The company is committed to continually developing its products to offer customers unique customer-oriented services that help them make their work more effective and efficient.

The expected revenue of Tecan Group is 883.64 M CHF. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Tecan Group is 79.52 M CHF. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Tecan Group is currently 31.08. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Tecan Group stock.

The price-to-sales ratio (P/S) of Tecan Group is currently 2.80. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Tecan Group stock.

The Eulerpool Quality Score for Tecan Group is 2/10.

The ISIN of Tecan Group is CH0012100191. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Tecan Group is 922557. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Tecan Group is TECN.SW. The ticker symbol is used to trade Tecan Group shares on the stock exchange.

Over the past 12 months, Tecan Group paid a dividend of 1.50 CHF . This corresponds to a dividend yield of about 0.77 %. For the coming 12 months, Tecan Group is expected to pay a dividend of 1.70 CHF.

The current dividend yield of Tecan Group is 0.77 %.

Tecan Group pays a dividend, distributed in the months of , , , .

Tecan Group paid dividends every year for the past 29 years.

For the upcoming 12 months, dividends amounting to 1.70 CHF are expected. This corresponds to a dividend yield of 0.87 %.

Tecan Group is assigned to the 'Health' sector.

To receive the latest dividend of Tecan Group from amounting to 1.5 CHF, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Tecan Group distributed 1.5 CHF as dividends.

The dividends of Tecan Group are distributed in CHF.

All fundamentals and in-depth analysis of Tecan Group

Our stock analysis for Tecan Group stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Tecan Group. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Tecan Group Stock
Tecan Group Revenue→
Tecan Group Stock
Tecan Group Net Income→
Tecan Group Stock
Tecan Group P/E→
Tecan Group Stock
Tecan Group P/S→
Tecan Group Stock
Tecan Group EBIT→
Tecan Group Stock
Tecan Group Dividend→
Tecan Group Stock
Tecan Group Directors Dealings→
Tecan Group Stock
Tecan Group Stocks→
Tecan Group Stock
Tecan Group Market capitalization→
Tecan Group Stock
Tecan Group Debt→
Tecan Group Stock
Tecan Group Liabilities→
Tecan Group Stock
Tecan Group Equity→
Tecan Group Stock
Tecan Group AAQS→
Tecan Group Stock
Tecan Group Employees→
Tecan Group Stock
Tecan Group ROE→
Tecan Group Stock
Tecan Group ROA→
Tecan Group Stock
Tecan Group ROCE→
Tecan Group Stock
Tecan Group News→
Tecan Group Stock
Tecan Group Analyst Price Targets→

Health Stocks

Techno Medica CoTcm Biotech InternationalTechno Medical PCLTCI GeneTectonic TherapeuticTaysha Gene TherapiesTego ScienceTasly Pharmaceutical Group CoTejnaksh HealthcareTarsus PharmaceuticalsTELA BioTarsons ProductsAll Stocks A–Z →